A polymeric diet rich in transforming growth factor beta 2 does not reduce inflammation in chronic 2,4,6-trinitrobenzene sulfonic acid colitis in pre-pubertal rats.


Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
10 Dec 2020
Historique:
received: 24 09 2020
accepted: 07 12 2020
entrez: 11 12 2020
pubmed: 12 12 2020
medline: 15 5 2021
Statut: epublish

Résumé

Pediatric Crohn's disease is characterized by a higher incidence of complicated phenotypes. Murine models help to better understand the dynamic process of intestinal fibrosis and test therapeutic interventions. Pre-pubertal models are lacking. We aimed to adapt a model of chronic colitis to pre-pubertal rats and test if a polymeric diet rich in TGF-β2 could reduce TNBS-induced intestinal inflammation and fibrosis. Colitis was induced in 20 five-week-old Sprague-Dawley male rats by weekly rectal injections of increasing doses of TNBS (90 mg/kg, 140 mg/kg and 180 mg/kg) for 3 weeks, while 10 controls received phosphate-buffered saline. Rats were anesthetized using ketamine and chlorpromazine. After first administration of TNBS, 10 rats were fed exclusively MODULEN IBD® powder, while remaining rats were fed breeding chow. Colitis was assessed one week after last dose of TNBS by histopathology and magnetic resonance colonography (MRC). Histological inflammation and fibrosis scores were higher in TNBS group than controls (p < 0.05 for both). MRC showed increased colon wall thickness in TNBS group compared to controls (p < 0.01), and increased prevalence of strictures and target sign (p < 0.05). Colon expression of COL1A1, CTGF, α-SMA and COX-2 did not differ between TNBS rats and controls. TNBS colitis was not associated with growth failure. Treatment with MODULEN IBD® was associated with growth failure, increased colon weight/length ratio (p < 0.01), but did not affect histological scores or MRI characteristics. Colon expression of α-SMA was significantly lower in the MODULEN group versus controls (p = 0.005). Features of chronic colitis were confirmed in this model, based on MRC and histopathology. Treatment with MODULEN did not reverse inflammation or fibrosis.

Sections du résumé

BACKGROUND BACKGROUND
Pediatric Crohn's disease is characterized by a higher incidence of complicated phenotypes. Murine models help to better understand the dynamic process of intestinal fibrosis and test therapeutic interventions. Pre-pubertal models are lacking. We aimed to adapt a model of chronic colitis to pre-pubertal rats and test if a polymeric diet rich in TGF-β2 could reduce TNBS-induced intestinal inflammation and fibrosis.
METHODS METHODS
Colitis was induced in 20 five-week-old Sprague-Dawley male rats by weekly rectal injections of increasing doses of TNBS (90 mg/kg, 140 mg/kg and 180 mg/kg) for 3 weeks, while 10 controls received phosphate-buffered saline. Rats were anesthetized using ketamine and chlorpromazine. After first administration of TNBS, 10 rats were fed exclusively MODULEN IBD® powder, while remaining rats were fed breeding chow. Colitis was assessed one week after last dose of TNBS by histopathology and magnetic resonance colonography (MRC).
RESULTS RESULTS
Histological inflammation and fibrosis scores were higher in TNBS group than controls (p < 0.05 for both). MRC showed increased colon wall thickness in TNBS group compared to controls (p < 0.01), and increased prevalence of strictures and target sign (p < 0.05). Colon expression of COL1A1, CTGF, α-SMA and COX-2 did not differ between TNBS rats and controls. TNBS colitis was not associated with growth failure. Treatment with MODULEN IBD® was associated with growth failure, increased colon weight/length ratio (p < 0.01), but did not affect histological scores or MRI characteristics. Colon expression of α-SMA was significantly lower in the MODULEN group versus controls (p = 0.005).
CONCLUSION CONCLUSIONS
Features of chronic colitis were confirmed in this model, based on MRC and histopathology. Treatment with MODULEN did not reverse inflammation or fibrosis.

Identifiants

pubmed: 33302890
doi: 10.1186/s12876-020-01574-8
pii: 10.1186/s12876-020-01574-8
pmc: PMC7731574
doi:

Substances chimiques

Transforming Growth Factor beta1 0
Transforming Growth Factor beta2 0
Trinitrobenzenes 0
sym-trinitrobenzene 2H75703R1X
Trinitrobenzenesulfonic Acid 8T3HQG2ZC4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

416

Références

Aliment Pharmacol Ther. 2000 Mar;14(3):281-9
pubmed: 10735920
J Pediatr Gastroenterol Nutr. 2010 Mar;50(3):240-50
pubmed: 20118800
World J Gastroenterol. 2016 Jun 14;22(22):5154-64
pubmed: 27298558
Environ Res. 2017 Jan;152:233-243
pubmed: 27810681
Am J Physiol Gastrointest Liver Physiol. 2011 May;300(5):G703-8
pubmed: 21233275
JPEN J Parenter Enteral Nutr. 2005 Jul-Aug;29(4 Suppl):S126-8; discussion S129-33, S184-8
pubmed: 15980274
Ann Med Surg (Lond). 2016 Aug 19;11:9-15
pubmed: 27656280
Hepatogastroenterology. 2005 Nov-Dec;52(66):1698-702
pubmed: 16334760
Eur J Gastroenterol Hepatol. 2017 Feb;29(2):125-134
pubmed: 27748673
J Dig Dis. 2012 Aug;13(8):421-9
pubmed: 22788928
Magn Reson Med. 2010 Apr;63(4):922-9
pubmed: 20373393
Mediators Inflamm. 2018 Feb 15;2018:8430614
pubmed: 29670469
Gastroenterology. 2017 Feb;152(2):340-350.e6
pubmed: 27720839
Arch Dis Child. 2014 May;99(5):420-6
pubmed: 24395646
J Comput Assist Tomogr. 2018 Sep/Oct;42(5):688-696
pubmed: 29958199
J Crohns Colitis. 2014 Oct;8(10):1147-65
pubmed: 24731838
PLoS One. 2014 Jul 07;9(7):e100921
pubmed: 25000184
Microb Biotechnol. 2017 Mar;10(2):480-491
pubmed: 27873488
Inflamm Bowel Dis. 2015 Jun;21(6):1248-59
pubmed: 25989337
J Crohns Colitis. 2014 Oct;8(10):1179-207
pubmed: 24909831
Gastroenterology. 2003 Dec;125(6):1750-61
pubmed: 14724828
Eur J Gastroenterol Hepatol. 2017 Aug;29(8):926-931
pubmed: 28471820
Am J Physiol Gastrointest Liver Physiol. 2012 Oct;303(7):G786-801
pubmed: 22878121
J Dairy Sci. 2016 Apr;99(4):2488-2501
pubmed: 26805965
Inflamm Bowel Dis. 2009 Apr;15(4):534-45
pubmed: 19058230
J Pediatr Gastroenterol Nutr. 2006 Jan;42(1):53-8
pubmed: 16385254
Fibrogenesis Tissue Repair. 2011 Feb 01;4(1):4
pubmed: 21284856
J Magn Reson Imaging. 2015 Sep;42(3):801-10
pubmed: 25504823
Am J Physiol Gastrointest Liver Physiol. 2019 Oct 1;317(4):G453-G462
pubmed: 31411504
J Dig Dis. 2020 Jun;21(6):342-350
pubmed: 32418328
Inflamm Bowel Dis. 2016 Jan;22(1):241-7
pubmed: 26588089
Scand J Gastroenterol. 2015 Jan;50(1):53-65
pubmed: 25523556
Gut. 2000 May;46(5):694-700
pubmed: 10764714
Eur J Histochem. 2014 Dec 17;58(4):2457
pubmed: 25578979
J Dig Dis. 2020 Jun;21(6):306-307
pubmed: 32407586

Auteurs

Claire Dupont-Lucas (C)

INSERM UMR 1073, Institute for Biomedical Research, Rouen University, Rouen, France. dupont-c@chu-caen.fr.
Department of Pediatrics, Caen University Hospital, Caen, France. dupont-c@chu-caen.fr.
Department of Nutrition, Rouen University Hospital, Rouen, France. dupont-c@chu-caen.fr.

Rachel Marion-Letellier (R)

INSERM UMR 1073, Institute for Biomedical Research, Rouen University, Rouen, France.
Department of Nutrition, Rouen University Hospital, Rouen, France.

Mathilde Pala (M)

INSERM UMR 1073, Institute for Biomedical Research, Rouen University, Rouen, France.
Department of Nutrition, Rouen University Hospital, Rouen, France.

Charlène Guerin (C)

INSERM UMR 1073, Institute for Biomedical Research, Rouen University, Rouen, France.
Department of Nutrition, Rouen University Hospital, Rouen, France.

Asma Amamou (A)

INSERM UMR 1073, Institute for Biomedical Research, Rouen University, Rouen, France.
Department of Nutrition, Rouen University Hospital, Rouen, France.

Marine Jarbeau (M)

INSERM UMR 1073, Institute for Biomedical Research, Rouen University, Rouen, France.
Department of Nutrition, Rouen University Hospital, Rouen, France.

Christine Bôle-Feysot (C)

INSERM UMR 1073, Institute for Biomedical Research, Rouen University, Rouen, France.
Department of Nutrition, Rouen University Hospital, Rouen, France.

Lionel Nicol (L)

INSERM UMR 1096, Institute for Biomedical Research, Rouen University, Rouen, France.
Department of Nutrition, Rouen University Hospital, Rouen, France.

Amelyne David (A)

INSERM UMR 1096, Institute for Biomedical Research, Rouen University, Rouen, France.
Department of Nutrition, Rouen University Hospital, Rouen, France.

Moutaz Aziz (M)

Department of Pathology, Rouen University Hospital, Rouen, France.
Department of Nutrition, Rouen University Hospital, Rouen, France.

Elodie Colasse (E)

Department of Pathology, Rouen University Hospital, Rouen, France.
Department of Nutrition, Rouen University Hospital, Rouen, France.

Céline Savoye-Collet (C)

Department of Nutrition, Rouen University Hospital, Rouen, France.
Department of Radiology, Rouen University Hospital, Rouen, France.
QUANTIF-LITIS EA 4108, Rouen University, Rouen, France.

Guillaume Savoye (G)

INSERM UMR 1073, Institute for Biomedical Research, Rouen University, Rouen, France.
Department of Nutrition, Rouen University Hospital, Rouen, France.
Department of Gastroenterology, Rouen University Hospital, Rouen, France.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH